Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

935 790

Amortization of deferred financing

charges 131 110 87

Interest income (542) (503) (374)

-------------------------------------------------------------------------

Loss from operation for the period 12,543 9,638 17,909

-------------------------------------------------------------------------

(Gain) on sale of shares (6,299)

-------------------------------------------------------------------------

Net (earnings)/loss and other

comprehensive income for the

period 6,244 9,638 17,909

-------------------------------------------------------------------------

Basic and diluted loss per common

share $ 0.03 $ 0.05 $ 0.10

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number of common

shares outstanding used in the

calculation of basic and diluted

loss per share 215,084 204,860 173,523

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Note re the financial statement information above:

On July 10, 2007 (the "Arrangement Date"), the Company completed a plan of arrangement and corporate reorganization with 4325231 Canada Inc., formerly Lorus Therapeutics Inc., ("Old Lorus"), 6707157 Canada Inc. and Pinnacle International Lands Inc (the "Arrangement"). As a result of the plan of arrangement and reorganization, among other things, each common share of Old Lorus was exchanged for one common share of the Company and the assets (excluding certain future ta
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 Alton ... thetelegraph.com dated May 15, 2013 said that their presence ... help other bed bug sufferers avoid such big spending, My ... bugs inexpensively. , It was said in the report ... an exterminator, MCP related. Apart from that, its employees also ...
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 ... tracking to reporting eLearning solution using Tin Can ... and dashboard tool. CLD is a leading developer ... and medical device companies worldwide. , Tin ... standard that helps learners and trainers more accurately ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
Breaking Biology Technology:Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3
... WOODCLIFF LAKE, N.J., Nov. 20 Par Pharmaceutical Companies, ... the U.S. District Court for the District of New ... temporary restraining order (TRO) halting sales of Teva,s generic ... the Court,s Order against Teva, AstraZeneca agreed and that ...
... 20 At a meeting of the Board,of Directors of ... of fifty cents($0.50) per share on the outstanding shares of ... of record at the close of business,on December 12, 2008. ... of the world,s largest research-driven pharmaceutical and,health care products companies. ...
... Sigma-Aldrich (Nasdaq: SIAL ),announced today the global ... MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are,expected ... in their RNAi,research with the highest purity and quality ... are believed to be well suited to target,validation and ...
Cached Biology Technology:Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension 2Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2
(Date:5/22/2013)... Calif., May 22, 2013 Early screening for prostate ... pregnancy testing is for women, thanks to UC Irvine ... American Chemical Society . , After more than a ... way to clearly identify clinically usable markers for prostate ... detected far sooner, with greater accuracy and at dramatically ...
(Date:5/21/2013)... considered in the management of natural resources, and ... help them recognize and respond to the relationships ... , Place-Based Conservation: Perspectives from the Social ... Northwest Research Station,s Linda Kruger, can help managers ... is published by Springer Verlag and is available ...
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3MU researchers develop radioactive nanoparticles that target cancer cells 2
... Exceptionally preserved fossils of insect cocoons have allowed researchers ... role in food webs devoted to consuming rotting dinosaur ... the scientific journal Palaeontology . The approximately ... dinosaurs were discovered in 1989 in the Patagonia region ...
... decade that has passed since the completion of the ... grown increasingly aware of a problem ironically generated by ... the age of genomics -- including DNA sequencing, gene ... other information-rich inquiries -- generate quantities of raw data ...
... a crucial factor underlying the development of emphysema, according to ... in mice that have short telomeres, there was a significant ... said Mary Armanios, MD, assistant professor of oncology at the ... ahead of the print edition of the American Journal ...
Cached Biology News:Fossil forensics reveals how wasps populated rotting dinosaur eggs 2Scientists to assemble 'knowledgebase' on plants, microbes, to aid US biofuel, environment efforts 2Scientists to assemble 'knowledgebase' on plants, microbes, to aid US biofuel, environment efforts 3Research links telomere length to emphysema risk 2
... AgarACE Enzyme(a) is a unique agarose-digesting enzyme ... recovery of intact DNA or RNA from ... that low melting point (LMP) agarose melted ... equilibrated to the reaction temperature before hydrolysis. ...
...
... proteins (NMPs) make up the internal structural framework ... functions as DNA replication, RNA synthesis, and hormone ... shown to be highly insoluble in vitro ... releases soluble nuclear matrix proteins that can be ...
Request Info...
Biology Products: